Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals

Next Previous
X
Search
Drug Profile

PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals

Alternative Names: PEG haemoglobin; PEG haemoglobin carbon monoxide; PEG-bHb-CO; PEG-COHb; PEG-haemoglobin-CO; PEG-Hb; PEG-LEH; Pegylated carboxyhemoglobin bovine; Pegylated haemoglobin carbon monoxide; Polyethylene glycol modified bovine haemoglobin; PP-007 - Prolong Pharmaceuticals; Sanguinate

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzon Pharmaceuticals; Rutgers
  • Developer Prolong Pharmaceuticals
  • Class Anti-ischaemics; Antifibrotics; Haemoglobins; Polyethylene glycols; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Delayed graft function
  • Phase II Cerebral ischaemia; Stroke; Vaso-occlusive crisis
  • Preclinical Cystic fibrosis; Haemorrhagic shock
  • No development reported Beta-thalassaemia

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Stroke in USA (IV, Infusion)
  • 13 Nov 2024 Preclinical trials in Haemorrhagic shock in USA (Parenteral)
  • 30 Oct 2024 PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals receives Fast Track designation for Stroke [IV,Infusion] in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top